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the alleles other than A21 was not different among each group.Dinucleotide repeat polymorphism of matrix metalloprotein-
The calculated odds ratio for nephropathy in the noncarrier,ase-9 gene is associated with diabetic nephropathy.
heterozygote, or homozygote of A21 allele was 3.38, 1.97, andBackground. Although genetic susceptibility has been pro-
0.2, respectively. Furthermore, the promoter assay for theposed as an important factor for the development and progres-
MMP-9 gene revealed that the A21 allele had a higher promotersion of diabetic nephropathy, the definitive gene has not been
activity compared with other alleles. No significant correlationidentified. To identify the genetic marker for diabetic nephrop-
was observed between serum MMP-9 concentrations and theathy, we examined the association between the (A-C)n dinucle-
MMP-9 gene polymorphism.otide repeat polymorphism upstream of the matrix metallopro-
Conclusion. These results indicate that the patients with A21teinase-9 (MMP-9) gene and diabetic nephropathy in a group
allele of the MMP-9 gene may be protected from the develop-of Japanese patients with type 2 diabetes.
ment and progression of diabetic nephropathy. Thus, the micro-Methods. Patients were divided into three groups based on
satellite polymorphism upstream of the MMP-9 gene could betheir urinary albumin excretion rate (AER) and the stage of
a useful genetic marker for diabetic nephropathy.diabetic retinopathy as follows: uncomplicated group (U), nor-
mal albuminuria (AER20 g/min) without proliferative retin-
opathy and with the duration of diabetes more than 20 years
(N  32); microalbuminuria group (M), 20  AER  200 g/ Diabetic nephropathy is one of the most common causesmin (N  155); overt nephropathy group (O), AER  200 g/
of renal death in various countries, including Japan. Poormin (N  63). The region containing the dinucleotide repeat
glycemic control of diabetes has been indicated as theupstream of MMP-9 gene was amplified by polymerase chain
reaction (PCR). The amplified products were analyzed with 7% most important cause of diabetic nephropathy [1], and
formamide/urea acrylamide gel electrophoresis. The promoter strict glycemic control was shown to prevent the develop-
constructs of the MMP-9 gene were transfected with the ment and progression of diabetic microangiopathy, in-CMV--galactosidase construct into 293 cells using the lipo-
cluding nephropathy, in both type 1 [2] and type 2 diabe-some method. Twenty-four hours after transfection, cells were
tes [3, 4]. On the other hand, certain genetic factors haveharvested, and luciferase and -galactosidase activities were
measured. been proposed to be responsible for the development
Results. Nine alleles of the dinucleotide repeat polymorphism and progression of diabetic nephropathy [5–7]. This hy-
(17 to 25 repeats) were identified, and the frequency of each pothesis is supported by the observation of familial clus-allele in diabetic subjects was not different from that in nondia-
tering of diabetic nephropathy in Caucasians [8–10] andbetic controls. The frequency of the allele containing 21 repeats
in Pima Indians [11]. Although efforts to identify the(A21) was most abundant (42.4% in control and 45.6% in dia-
betic subjects), followed by the allele with 23 repeats (A23; genes responsible for the development and progression
35.4% in control and 27.6% in diabetic subjects). The A21 allele of diabetic microangiopathy have been made and several
was less frequent in M and O than U (O, 38.9%; M, 45.5%; U, candidate genes shown to be associated with diabetic59.3%, 2  7.18; P  0.05, O vs. U), while the frequency of
microangiopathy [12–17], the definitive genes have not
been identified yet.
Diabetic nephropathy is characterized histologically byKey words: type 2 diabetes, genetic marker, A21 allele, progressive
renal disease, Japanese type 2 diabetes, microsatellite polymorphism. the overaccumulation of extracellular matrix (ECM) pro-
teins, such as type IV collagen, in the glomerular mesan-Received for publication November 7, 2000
gium [18]. The overaccumulation of type IV collagen inand in revised form April 10, 2001
Accepted for publication April 19, 2001 diabetic glomeruli has been considered to be caused not
only by the overproduction of type IV collagen by glomer- 2001 by the International Society of Nephrology
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ular mesangial cells [19], but also by the decrease in the or obesity also were examined. A written informed con-
sent for DNA analysis was obtained. After overnightdegradation of matrix proteins [20]. Matrix metallopro-
teinase-9 (MMP-9) plays a key role in the metabolism of fasting, blood samples were taken for DNA analysis and
for the measurement of clinical parameters such as fast-ECM proteins and has an ability to degrade type IV col-
lagen. A decrease in the expression of the MMP-9 gene ing plasma glucose, hemoglobin A1c, and serum creati-
nine. Serum MMP-9 concentrations were measured bywas found in glomeruli of diabetic rats [21], suggest-
ing that the alteration of MMP-9 gene expression might enzyme-linked immunosorbent assay (ELISA) using
monoclonal antibodies as previously reported [28]. Theplay a role in the development and progression of dia-
betic nephropathy. protocol was approved by the ethical committee of Shiga
University of Medical Science.Although the MMP-9 gene was originally shown to
be located on chromosome 16 [22], a recent study has
Determination of the number of dinucleotide repeatidentified it on chromosome 20 [23], where the existence
at 5 flanking region of the MMP-9 geneof the locus of diabetic nephropathy has been reported
[24]. The regulation of MMP-9 gene expression has been DNA samples were extracted from peripheral leuko-
cytes with a DNA purification kit (QIAamp Blood kit;examined, and several cis-acting elements were identi-
fied in the 5 end of the MMP-9 gene [25, 26]. The exis- Qiagen Inc., Chatsworth, CA, USA). The region contain-
ing the dinucleotide repeat upstream of the MMP-9 genetence of a dinucleotide repeat polymorphism was also
found at 90 bp upstream of the transcriptional initiation was amplified by polymerase chain reaction (PCR) using
primers reported previously [21]: CLG4BF, 5-GACTTsite of MMP-9 gene [23]. Because this microsatellite was
very close to the cap site, we hypothesized that this micro- GGCAGTGGAGACTGCGGGCA-3; and CLG4BR,
5-GACCCCACCCCTCCTTGACAGGCAA-3. PCRsatellite polymorphism might affect the susceptibility to
diabetic nephropathy. To address this issue, we deter- reaction was carried out in a 15 L mixture contain-
ing 50 to 200 ng genomic DNA or 1 ng of control plas-mined the genotypes of dinucleotide repeat polymor-
phism of the MMP-9 gene and examined the association mid, 9 pmol CGL4BF, and 1 pmol of [32P] end-labeled
CGL4BF, 10 pmol CGL4BR, 10 mmol/L Tris-HCl, pH 8.3,between this polymorphism and diabetic nephropathy
in Japanese subjects with type 2 diabetes. 50 mmol/L KCl, 0.1% TritonX-100, 1.5 mmol/L MgCl2,
200 mol/L dNTPs, and 1 U Taq polymerase. After an
initial denaturation at 94	C for five minutes, the samples
METHODS
were subjected to 25 cycles of amplification, consisting of
Subjects denaturation for one minute at 94	C, annealing for one
minute at 69	C, and extension for one minute at 72	C,A total of 501 type 2 diabetic patients who were regu-
larly followed in the outpatient clinic of Third Depart- followed by final extension at 72	C for ten minutes in
a thermal cycler (PJ-2000; Takara BioMedicals, Shiga,ment of Medicine, Shiga University of Medical Science
were first enrolled. The stage of diabetic nephropathy Japan). The amplified products were analyzed with 7%
formamide/urea acrylamide gel electrophoresis [29, 30].was defined based on the urinary albumin excretion rates
(AERs) in 24-hour urine samples measured by radioimmu- Control plasmid, PGL2MMP-9, containing 0.65kb of the
5 flanking sequence of human MMP-9 gene with 20 ACnoassay as follows: normoalbuminuria, AER 20g/min;
microalbuminuria, 20  AER  200 g/min; and overt repeat was used as a control plasmid.
nephropathy, 200 g/min  AER. The determination of
Measurement of promoter activity for theAER was made more than twice in each individual. The
MMP-9 genediagnosis of the stage of diabetic retinopathy was made
by an ophthalmologist. Patients were divided into three The DNA fragments of the MMP-9 gene promoter were
amplified from the genomic DNA of the patients by PCRgroups according to the duration of diabetes and the
stages of nephropathy and retinopathy. The uncompli- using the following primers: forward primer, 5-AAT
TCTCGAGATTCAGCCTGCGGAAGACAG-3, andcated group was defined by the same diagnostic criteria
as previously reported [27]; the duration of diabetes was reverse primer, 5-ATATAAGCTTTGGTGAGGGCA
GAGGTGTCT-3. The PCR reaction was carried out20 years or more and normoalbuminuria without prolif-
erative retinopathy (N  32). Patients with nephropathy in 50 L mixture containing 50 to 200 ng genomic DNA,
10 pmol of each primer, 10 mmol/L Tris-HCl, pH 8.3,were divided into two groups: microalbuminuria (N 
155) and overt nephropathy (N  63). The remaining 50 mmol/L KCl, 0.1% Triton X-100, 1.5 mmol/L MgCl2,
200 mol/L dNTPs, and 1 U Taq polymerase. After thepatients (N  251), who had normoalbuminuria with a
duration of diabetes of less than 20 years, were excluded initial denaturation at 94	C for five minutes, the samples
were subjected to 30 cycles of amplification, consistingfrom the present study. Seventy-two control subjects who
showed a normal pattern in a 75 g oral glucose tolerance of denaturation for one minute at 94	C, annealing for
one minute at 55	C, and an extension for one minute attest and who did not have any family history for diabetes
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Table 1. Allelic frequency of dinucleotide repeat polymorphism in the promoter of the matrix metalloproteinase-9 gene (MMP-9)
Allele (repeat) A17 (17) A18 (18) A19 (19) A20 (20) A21 (21) A22 (22) A23 (23) A24 (24) A25 (25)
Control (N72) 0 (0) 0 (0) 2.1 (3) 2.8 (4) 42.4 (61) 13.9 (20) 35.4 (51) 2.1 (3) 1.4 (2)
Diabetes (N250) 0.2 (1) 0.2 (1) 0.6 (3) 9.8 (49) 47.6 (238) 11.0 (55) 27.4 (137) 3.0 (15) 0.2 (1)
The number of chromosomes is in the parentheses.
Table 2. Clinical characteristics
Uncomplicated Microalbuminuria Overt nephropathy
N32 N155 N63
Age year 64.7
9.3 63.6
9.5 62.3
8.7
Sex male:female 20:12 105:48 39:24
Duration years 25.1
6.3a 13.6
9.1b 17.4
9.3
HbA1c % 7.3
1.1 7.4
1.1 7.7
1.2
AER lg/min 8.7 (5.314.5) 52.5 (24.4114.3)a 851 (2542904)a
SCr mmol/L 61.4
19.6 62.9
17.6 95.0
52.3
CCr mL/min 115
45 120
48c 87
49
Plasma MMP-9 ng/mL 25.5
10.9 30.0
16.8 30.6
18.0
Data are mean 
 SD or ratio, and AER data are geometric mean (10th to 90th percentile). Abbreviations are: AER, albumin excretion rate; SCr, serum creatinine;
CCr, creatinine clearance; MMP-9, matrix metalloproteinase-9; HbA1c, glycosylated hemoglobin A.
a P  0.005 vs. other groups
b P  0.05 vs. overt nephropathy
c P  0.0001 vs. overt nephropathy
Table 3. Association of dinucleotide repeat polymorphism72	C followed by a final extension at 72	C for ten minutes
in the promoter of matrix metalloproteinase-9 gene and
in a thermal cycler. The amplified products were purified diabetic nephropathy
from acrylamide gels and subcloned into a PGL2 basic
Uncomplicated Microalbuminuria Overt nephropathyvector (Promega, Madison, WI, USA) at the Xba Allele N32 N155 N63
I-HindIII site. The sequences of the promoter constructs
A20 6.3 (4) 10.6 (33) 15.1 (19)
were analyzed by dye terminater methods (ABI PRISM A21 59.3 (38) 45.5 (141) 38.9 (49)a
A22 10.9 (7) 12.6 (39) 8.7 (11)310; Applied Biosystems, Foster City, CA, USA). After
A23 15.6 (10) 27.7 (86) 33.3 (42)large-scale purification, the promoter constructs of the Others 7.9 (5) 3.6 (11) 4.0 (5)
MMP-9 gene were transfected with CMV--galactosi-
The frequency of each allele is shown. The number of chromosomes is in the
dase construct into 293 cells using liposome method parentheses.
a P  0.05 vs. uncomplicated after correction with Bonferroni’s multiple com-(LipofectoAMINE PLUS; Life Technologies, Rock-
parison.
ville, MD, USA); 24 hours after transfection, cells were
harvested, and luciferase and -galactosidase activities
were measured.
allele in diabetic subjects was not different from that in
Statistical analysis nondiabetic subjects (Table 1).
The clinical characteristics of each group are summa-Comparisons among three or more groups were ana-
rized in Table 2. The duration of diabetes was signifi-lyzed by one-way analysis of variance followed by the
cantly longer in the uncomplicated group than that inScheffe test to evaluate statistical significance between
other groups. The concentrations of serum creatinine wereany two groups. The frequency of each genotype was
significantly higher in the patients with overt nephropathyanalyzed by 2 3 contingency tables followed by Bonfer-
than in other groups. The association between the micro-roni’s multiple comparisons.
satellite polymorphism and diabetic nephropathy is sum-
marized in Table 3. The frequency of the A21 allele was
RESULTS significantly lower in the overt nephropathy group as
Nine alleles of dinucleotide repeat polymorphism (17 compared with the uncomplicated group (2  7.18, P 
0.05). An increase in the frequency of A23 allele wasto 25 repeats) were identified in the MMP-9 gene, and
the most common allele was the one that had a 21 di- observed in patients with overt nephropathy as compared
with patients of uncomplicated group, although the dif-nucleotide repeat (A21 allele: 45.6% in diabetics and
42.4% in control), followed by A23 (27.6% in diabetics ference was not statistically significant (33.3% in overt
nephropathy vs. 15.6% in uncomplicated, 2  6.69, P and 35.4% in control; Table 1). The frequency of each
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Table 4. Contribution of the A21 allele (21 repeats) to the degradation of ECM proteins. MMP-9, also termed as
development of diabetic nephropathy
gelatinase B, is one of the important enzymes responsible
Uncomplicated Nephropathya Odds ratio (95% CI) for the degradation of ECM proteins and is able to de-
Non-carrier 4 71 3.38 (1.110.5) grade type IV collagen. Recently, MMP-9 gene expres-
Carrier 28 147 1 sion has been reported to be decreased in the tissues from
Heterozygote 10 103 1.97 (1.04.0)
diabetic animals as compared with the tissues from con-Othersb 22 115 1
Homozygote 18 44 0.2 (0.10.4) trol animals [21], suggesting the alteration of the expres-
Othersc 14 174 1 sion of the MMP-9 gene might affect the metabolism of
a Defined as microalbuminuria and overt nephropathy type IV collagen and thus lead to the progression of dia-
b Non-carrier and homozygote
betic glomerulosclerosis.c Non-carrier and heterozygote
Although the human MMP-9 gene was originally re-
ported to be located at chromosome 16 [22], a recent re-
port revealed that the MMP-9 gene was present on chro-
0.03 before the correction with Bonferroni’s multiple mosome 20 [23]. The linkage analysis for the diabetic
comparisons, P  0.05 after the correction with Bonfer- nephropathy has been performed in the Pima Indians
roni’s multiple comparisons). The frequency of other and has identified that the locus for diabetic nephropathy
alleles was not different among each group. We next is present in chromosome 20 as well as in chromosomes 3,
calculated the relative risk of the A21 allele for diabetic 7, and 9 [24]. From these observations, the MMP-9 gene
nephropathy. In this calculation, the microalbuminuria is proposed as one of the strong candidates for the de-
group and overt nephropathy group were combined as velopment and progression of diabetic nephropathy. The
the nephropathy group. As shown in Table 4, the odds regulation of the expression of the MMP-9 gene has been
ratio of the noncarrier of the A21 allele was 3.38, whereas studied, and the presence of several cis-acting elements
that of the A21 heterozygote and A21 homozygote was was identified at 5 flanking region of the MMP-9 gene
1.97 and 0.2, respectively, indicating that the A21 allele [25, 26]. Although a decrease in MMP-9 expression was
may be a protective allele for the progression and devel- found in diabetic animals [21], the element at the 5
opment of diabetic nephropathy. flanking region of the MMP-9 gene regulated by diabetic
The difference of promoter activity of the MMP-9 gene milieu has not been identified yet. The dinucleotide re-
among various numbers of the dinucleotide repeat is shown peat is present approximately 90 bp upstream from tran-
in Figure 1, where the promoter activity of the A21 allele scriptional initiation site of the MMP-9 gene. Because
was significantly elevated than those of other alleles. The this microsatellite is very close to the transcriptional initi-
sequence of each construct other than the region of AC ation site and there are several important transcription
dinucleotide repeat was not different among the con- factor binding sites, including the TRE, GC box, and
structs from each patient who had various numbers of nuclear factor-B binding site around this microsatellite
[22, 25], it is possible to hypothesize that the polymor-dinucleotide repeat. On the other hand, no significant
phism of this microsatellite is linked to the transcriptionalcorrelation could be identified between the microsatel-
activity of the MMP-9 gene.lite polymorphism and serum MMP-9 concentrations
In the present study, we found nine alleles of a dinucle-(Table 5).
otide repeat polymorphism, the most common allele of
which was the one that had a 21 dinucleotide repeat. The
DISCUSSION allelic frequency of a dinucleotide repeat polymorphism
The present study indicates that dinucleotide repeat was not different between the control and diabetic sub-
polymorphism upstream of the MMP-9 gene contributes jects. However, the allelic frequency observed in the pres-
to the development and progression of diabetic nephrop- ent study is very different from that in Caucasian sub-
athy. The results suggest that the A21 allele (21 repeats) jects, in whom the most common allele was found to be
in the dinucleotide repeat polymorphism upstream of the one with 14 repeats [23], indicating that the ethnic
the MMP-9 gene is a protective allele for the develop- difference might be present in this dinucleotide repeat
ment and progression of diabetic nephropathy. Further- polymorphism. The present study clearly indicates that
more, the promoter analysis revealed that the promoter the frequency of A21 allele (21 repeats) in the dinucleo-
construct of MMP-9 with A21 allele has higher transcrip- tide repeat polymorphism upstream of the MMP-9 gene
tional activity as compared with those with other alleles. is significantly associated with the incidence of overt
Diabetic nephropathy is characterized histologically nephropathy in Japanese subjects with type 2 diabetes.
by the accumulation of ECM proteins, such as type IV The relative risk for the diabetic nephropathy according
collagen, in the renal glomeruli [18]. This accumulation to the presence of A21 allele also suggests that the A21
of ECM proteins is caused not only by the overproduc- allele is a protective allele for the development and pro-
gression of diabetic nephropathy.tion of ECM proteins, but also by the decrease in the
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Fig. 1. The difference in promoter activity among the luciferase constructs of matrix metalloproteinase-9 (MMP-9) gene promoter with various
number of dinucleotide repeats. Results were shown as mean 
 SEM determined by 10 independent experiments, and each experiment was
performed in triplicate. *P  0.049 vs. A18, P  0.003 vs. A22, P  0.09 vs. A23, and P  0.0026 vs. A24.
The expression of the MMP-9 gene has been reported MMP-9 could be regulated not only by the constitutive
expression, but also by the responsiveness to variousto be regulated by several factors such as transforming
growth factor- (TGF-) and 12-O-tetradecanoyl phor- stimuli activated under diabetic milieu. Because, as de-
scribed previously in this article, the microsatellite exam-bor 13-acetate (TPA), through the TGF- inhibitory
element and TPA-response element, respectively. The ined in this study was present at a very close position
to the transcriptional initiation site or several cis-actingexpression of TGF- was found to be up-regulated in
tissues of diabetic animals [31, 32] and in cells cultured elements of the MMP-9 gene, we speculated that this
polymorphism might function as a regulator of the tran-under high glucose conditions [31]. Furthermore, the ac-
tivation of protein kinase C, which could result in the scriptional activity of that MMP-9 gene under basal or
various pathological states such as diabetes mellitus. Thetranscriptional activation of activator protein (AP-1)
through the activation of mitogen-activated protein ki- present study indicates that the promoter activity of
MMP-9 varies according to the number of AC dinucleo-nase, was observed in diabetic glomeruli [32–34] as well
as cultured mesangial cells treated with high concentra- tide repeat, and that constructs with 21 repeats have a
higher promoter activity. Therefore, patients with thetion of glucose [34–36]. Therefore, the expression of
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Table 5. Relationship between the microsatellite polymorphism of REFERENCES
the MMP-9 gene promoter and plasma MMP-9 concentrations
1. Krolewski AS, Laffel LMB, Krolewski M, et al: Glycosylated
Allele A20 A21 A22 A23 hemoglobin and the risk of microalbuminuria in patients with insu-
lin-dependent diabetes mellitus. N Engl J Med 332:1251–1255, 1995Carrier 30.6
16.5 28.9
15.6 31.7
19.3 29.2
17.2
2. The Diabetes Control and Complications Trial Research(53) (174) (54) (117)
Group: The effect of intensive treatment of diabetes on the devel-Non-carrier 29.3
16.6 31.3
18.6 29.0
15.7 29.2
17.2
opment and progression of long-term complications in insulin-(196) (75) (195) (132)
dependent diabetes mellitus. N Engl J Med 329:977–986, 1993
Plasma MMP-9 concentrations are ng/mL. 3. UK Prospective Diabetes Study (UKPDS) Group: Intensive
Data are shown as mean 
 SD, and the number of patients is in parentheses. blood-glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in patients
with type 2 diabetes (UKPDS33). Lancet 352:837–853, 1998
A21 allele might have higher MMP-9 expression and 4. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy
prevents the progression of diabetic microvascular complicationsthus might be protected from the progression of diabetic
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renal disease in two generations of Pima Indians with type 2 (non-concentrations are not able to reflect tissue expression of
insulin-dependent) diabetes mellitus. Diabetologia 33:438–443, 1990
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of nephropathy in insulin-dependent diabetes mellitus. J Am Soccrosatellite polymorphism of the MMP-9 gene or with the
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